- Home
- CTO vs NGNE Comparison
CTO vs NGNE Comparison
Compare CTO & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | NGNE |
|---|---|---|
| Founded | 1902 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.2M | 744.9M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CTO | NGNE |
|---|---|---|
| Price | $19.67 | $23.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $24.60 | ★ $77.88 |
| AVG Volume (30 Days) | ★ 291.1K | 287.6K |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 7.68% | N/A |
| EPS Growth | ★ 122.86 | 0.93 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $149,545,000.00 | N/A |
| Revenue This Year | $18.22 | N/A |
| Revenue Next Year | $12.10 | N/A |
| P/E Ratio | $152.27 | ★ N/A |
| Revenue Growth | ★ 20.10 | N/A |
| 52 Week Low | $16.17 | $15.93 |
| 52 Week High | $22.71 | $43.66 |
Technical Indicators
Market Signals| Indicator | CTO | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 37.40 |
| Support Level | $19.49 | $18.68 |
| Resistance Level | $20.08 | $29.16 |
| Average True Range (ATR) | 0.46 | 2.06 |
| MACD | -0.05 | 0.30 |
| Stochastic Oscillator | 8.51 | 27.62 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.